Satellos Bioscience (NASDAQ:MSLE) Releases Quarterly Earnings Results

Satellos Bioscience (NASDAQ:MSLE) released its quarterly earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02), Zacks reports.

Satellos Bioscience Stock Performance

MSLE traded down $0.16 during midday trading on Friday, hitting $7.01. The stock had a trading volume of 43,311 shares, compared to its average volume of 38,248. The stock has a market capitalization of $146.02 million, a P/E ratio of -4.52 and a beta of 1.60. The company’s fifty day moving average is $7.52. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39.

Analysts Set New Price Targets

MSLE has been the subject of a number of research reports. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday. Wall Street Zen raised shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday. HC Wainwright boosted their price target on shares of Satellos Bioscience to $11.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Leerink Partners started coverage on Satellos Bioscience in a research report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.